NCT04746638 is a Phase 1 clinical trial of whole body study and SPECT with 99mTc-RM26 in Prostate Cancer, sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences.

Who is sponsoring NCT04746638?

NCT04746638 is sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences.

What drugs are being tested in NCT04746638?

Interventions in NCT04746638: whole body study and SPECT with 99mTc-RM26.

What condition does NCT04746638 study?

NCT04746638 studies Prostate Cancer, Breast Cancer Female.

Is NCT04746638 still recruiting?

NCT04746638 is currently completed. Last updated 28 November 2023.

Last reviewed 2023-11-28 · How we verify

NCT04746638

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m RM26

Completed Phase 1 Last updated 28 November 2023

What this trial tests

Phase 1 trial testing whole body study and SPECT with 99mTc-RM26 in Prostate Cancer in 10 participants. Completed in 1 June 2023.

Timeline

1 February 2021

Primary endpoint
19 May 2022

1 June 2023

Quick facts

Lead sponsor	Tomsk National Research Medical Center of the Russian Academy of Sciences
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	single
Primary purpose	diagnostic
Enrollment	10
Start date	1 February 2021
Primary completion	19 May 2022
Estimated completion	1 June 2023
Sites	1 location across Russia

Drugs / interventions tested

whole body study and SPECT with 99mTc-RM26

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →
Breast Cancer Female — all drugs for Breast Cancer Female →

Sponsor

Tomsk National Research Medical Center of the Russian Academy of Sciences

Who can join

Adults 18 to 70, any sex, with Prostate Cancer or Breast Cancer Female. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study should evaluate the biological distribution of 99mTc-RM26 in patients with prostate cancer and breast cancer. The primary objective are: 1. To assess the distribution of 99mTc- RM26 in normal tissues and tumors at different time intervals. 2. To evaluate dosimetry of 99mTc- RM26. 3. To study the safety and tolerability of the drug 99mTc- RM26 after a single injection in a diagnostic dosage. The secondary objective are: 1\. To compare the obtained 99mTc- RM26 SPECT imaging results with the data of CT and/or MRI and/or ultrasound examination and immunohistochemical (IHC) studies in prostate cancer and breast cancer patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Phase I Trial of [<sup>99m</sup>Tc]Tc-maSSS-PEG<sub>2</sub>-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors.
Chernov V, Rybina A, Zelchan R, Medvedeva A, et al · · 2023 · cited 25× · PMID 36980517 · DOI 10.3390/cancers15061631

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Tomsk National Research Medical Center of the Russian Academy of Sciences trials

Trials by the same sponsor.

NCT07457541 — Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI · Phase 1 · active not recruiting
NCT07475390 — 99mTc-1-thio-D-glucose SPECT/CT Versus 18F-Fluoroethyl-l-tyrosine PET/CT in Brain Tumor Imaging · NA · active not recruiting
NCT07292571 — Evaluation of Different Types of HER2 Expression in Breast Cancer Using [99mTc]Tc -ZHER2:4107 · Phase 2 · enrolling by invitation
NCT07275463 — [99mTc]Tc-DB8 Accumulation in Primary Tumor in Breast Cancer With Positive and Negative Estrogen Receptor Expression · Phase 2 · enrolling by invitation
NCT07018895 — Personalized Hypoxic-hyperoxic Preconditioning in Elderly People · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04746638 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tomsk National Research Medical Center of the Russian Academy of Sciences
Last refreshed: 28 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04746638.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing